Clinical Trial

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Study acronym: TREAT-CRS
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-09-03; most recent amendment 2026-06-15.
Status change: Not Yet Recruiting → Recruiting 2025-08-04
Trial Details
NCT Number NCT06030843
Lead Sponsor Chulalongkorn University
Conditions Empagliflozin in Cardiorenal Syndrome Type 1
Enrollment 200 participants
Start Date 2025-03-01
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-16